Shanghai SIMR Biotechnology Co., Ltd.
11
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia
Role: lead
The Pharmacokinetics (PK), Safety, Tolerability of SR750 (Formulation F1) in Healthy Volunteers
Role: lead
A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419
Role: lead
Efficacy and Safety of SR1375 in Adult Patients With CAP
Role: lead
The Safety, Tolerability, Pharmacokinetics(PK) of SR419 in Healthy Volunteers
Role: lead
The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers
Role: lead
The Pharmacokinetics (PK), Safety, Tolerability of SR750 in Healthy Volunteers
Role: lead
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375
Role: lead
The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers
Role: lead
The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers
Role: lead
To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)
Role: lead
All 11 trials loaded